Despite encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. These https://dillanvgik393020.bloginwi.com/75883144/the-medication-faces-is-meeting-pbm-challenges-the-look-of-reimbursement-fights